143 related articles for article (PubMed ID: 36880899)
21. Developing a cascade of care for opioid use disorder among individuals in jail.
Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
[TBL] [Abstract][Full Text] [Related]
22. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts.
Matsumoto A; Santelices C; Evans EA; Pivovarova E; Stopka TJ; Ferguson WJ; Friedmann PD
Int J Drug Policy; 2022 Nov; 109():103823. PubMed ID: 35994938
[TBL] [Abstract][Full Text] [Related]
23. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
Harrington C; Bailey A; Delorme E; Hano S; Evans EA
Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
[No Abstract] [Full Text] [Related]
24. Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.
Ryan DA; Montoya ID; Koutoujian PJ; Siddiqi K; Hayes E; Jeng PJ; Cadet T; McCollister KE; Murphy SM
J Subst Use Addict Treat; 2023 Mar; 146():208943. PubMed ID: 36880906
[TBL] [Abstract][Full Text] [Related]
25. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
Doernberg M; Krawczyk N; Agus D; Fingerhood M
Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
[TBL] [Abstract][Full Text] [Related]
26. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
Cheng A; Badolato R; Segoshi A; McDonald R; Malone M; Vasudevan K; Badiei B; Sugarman A; Macdonald R; Mangat J; Giftos J; Lee JD; Tofighi B
Addict Sci Clin Pract; 2022 Jan; 17(1):4. PubMed ID: 35093164
[TBL] [Abstract][Full Text] [Related]
27. Use of non-prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration.
Gryczynski J; Lee JD; Dusek K; McDonald R; Sharma A; Malone M; Monico LB; Cheng A; DeVeaugh-Geiss A; Chilcoat HD
J Subst Abuse Treat; 2021 Aug; 127():108349. PubMed ID: 34134866
[TBL] [Abstract][Full Text] [Related]
28. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
[TBL] [Abstract][Full Text] [Related]
29. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
Treitler PC; Enich M; Reeves D; Crystal S
Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
[No Abstract] [Full Text] [Related]
30. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives.
Pivovarova E; Evans EA; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
Drug Alcohol Depend; 2022 May; 234():109394. PubMed ID: 35349918
[TBL] [Abstract][Full Text] [Related]
31. The association between attitudes and the provision of medications for opioid use disorder (MOUD) in United States jails.
Pfaff A; Cochran A; Vechinski J; Molfenter T; Zayas-Cabán G
Drug Alcohol Depend Rep; 2024 Mar; 10():100211. PubMed ID: 38205144
[TBL] [Abstract][Full Text] [Related]
32. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
[TBL] [Abstract][Full Text] [Related]
33. Facilitators and barriers to adopting or expanding medications for opioid use disorder provision in rural Colorado jails: a qualitative analysis.
McNeely HL; Schreiber TL; Swann WL; Amura CR
Health Justice; 2024 Jun; 12(1):26. PubMed ID: 38842589
[TBL] [Abstract][Full Text] [Related]
34. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
[TBL] [Abstract][Full Text] [Related]
35. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
[TBL] [Abstract][Full Text] [Related]
36. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
Gordon MS; Mitchell SG; Blue TR; Vocci FJ; Fishman MJ; Murphy SM; Couvillion K; Maher K; Ryan D; Wenzel K; Danner ML; Jarvis DK
J Subst Abuse Treat; 2021 Sep; 128():108241. PubMed ID: 33339633
[TBL] [Abstract][Full Text] [Related]
37. The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use disorder treatment outcomes following release from jail.
Howell BA; Puglisi L; Clark K; Albizu-Garcia C; Ashkin E; Booth T; Brinkley-Rubinstein L; Fiellin DA; Fox AD; Maurer KF; Lin HJ; McCollister K; Murphy S; Morse DS; Shavit S; Wang K; Winkelman T; Wang EA
J Subst Abuse Treat; 2021 Sep; 128():108315. PubMed ID: 33583610
[TBL] [Abstract][Full Text] [Related]
38. The impact of the opioid crisis on U.S. state prison systems.
Scott CK; Dennis ML; Grella CE; Mischel AF; Carnevale J
Health Justice; 2021 Jul; 9(1):17. PubMed ID: 34304335
[TBL] [Abstract][Full Text] [Related]
39. Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis.
Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
J Subst Use Addict Treat; 2024 Mar; 158():209254. PubMed ID: 38072387
[TBL] [Abstract][Full Text] [Related]
40. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
